PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of worldjradiolLink to Publisher's site
 
World J Radiol. 2009 December 31; 1(1): 45–49.
Published online 2009 December 31. doi:  10.4329/wjr.v1.i1.45
PMCID: PMC2999305

Neuroimaging in human prion disease: Searching in the mist

Abstract

Human prion disease is a rare, uniformly fatal neurodegenerative disorder.Its precise pathogenesis is obscure. The clinical profile of the disease differs among its various forms. There are no definitive diagnostic tests (except for brain biopsy) or proven treatment. To increase the clinical diagnostic sensitivity and specificity, three laboratory tests, including electroencephalogram, cerebrospinal fluid testing for 14-3-3 protein, and magnetic resonance imaging, are currently used. Additionally, proton magnetic resonance spectroscopy, positron emission tomography and single photon emission computed tomography can provide interesting and novel results in the research of human prion disease.

Keywords: Human prion disease, Creutzfeldt-Jakob disease, Neuroimaging, Magnetic resonance imaging

INTRODUCTION

Human prion disease is a rare, uniformly fatal progressive neurodegenerative disorder, characterized by the deposition of an abnormal prion protein (PrP) in the central nervous system[1]. The most common form of human prion disease is Creutzfeldt-Jakob disease (CJD) and the whole nosological spectrum has been further divided into four categories. (1) Sporadic CJD (sCJD) arising from either a spontaneous PrP gene mutation or from a stochastic PrP structural change to the abnormal form. The host codon 129 genotype and the molecular strain of the deposited prion agent affect the phenotype[1,2]; (2) Iatrogenic prion disease, caused by infection (prion transmission) from medical (blood transfusion, human growth hormone) or surgical (corneal, dura mater grafts) procedures[1,2]; (3) Variant CJD (vCJD) which is causally linked to bovine (cattle) spongiform encephalopathy prion agent[1-3]; and (4) Inherited or genetic prion disease, caused by autosomal dominant PrP gene mutations (such as E220k, P102L) or insertions (such as ins144bp, ins24bp) on human chromosome 20[1,2]. The clinicopathological spectrum is further influenced by polymorphisms at codon 129 of the PrP gene[1-3].

The precise pathogenetic mechanism underlying the neurological illness is at present obscure. The clinical profile of the disease differs among its various forms. Early ante-mortem diagnosis is challengingly difficult and no definitive diagnostic tests (except for brain biopsy) or proven treatment modalities are available. Most importantly, other potentially treatable diseases including infectious, inflammatory, autoimmune, toxic, and metabolic diseases should initially be excluded[1-4].

In addition to abnormal PrP straining, the neuropathological changes are characterized by neuronal loss, astrocytic gliosis, and spongiform change[1-3]. The initial diagnostic suspicion of prion disease is clinical, usually raised by various combinations of rapidly progressive cognitive impairment, psychiatric features, cerebellar ataxia, myoclonus, visual disturbances, pyramidal or extrapyramidal signs and terminal akinetic mutism[3,4]. However, significant clinical heterogeneity and different phenotypes occur in all forms of human prion disease [sCJD, vCJD, genetic and iatrogenic CJD (iCJD)], and are paralleled to variations in neuropathology[1-3,5].

DIAGNOSTIC LABORATORY TESTS

Three laboratory tests, including electroencephalogram (EEG), cerebrospinal fluid (CSF) testing for 14-3-3 protein, and magnetic resonance imaging (MRI) are currently used to increase the clinical diagnostic sensitivity and specificity[2,6,7], and have been included in the World Health Organization (WHO) diagnostic criteria for vCJD[8] and sCJD[9]. The EEG, in around two thirds of cases, may show progressive deterioration with the appearance of periodic sharp wave complexes, the absence of which does not exclude the diagnosis[1,6]. Also, these EEG complexes may be present in other conditions, such as hepatic encephalopathy, drug-heavy metals toxicity and Alzheimer’s disease, while they are absent in vCJD[1].

CSF 14-3-3 is a normal neuronal protein that is released into the CSF following neuronal damage, with no specific connection to CJD[1]. However, it shows a surprisingly high specificity and sensitivity (around 94%) to sCJD[6] and therefore it should be only valid in the appropriate clinical setting[1]. When this test is used in unselected patients with rapidly progressive dementia, false positive results can be found in 12% of them[10]. Furthermore, fatal insomnia, a rare inherited form of prion disease, does not increase the CSF levels of 14-3-3 protein, in almost all cases[11].

Over the past decade, the non-invasive nature of MRI, the improved MR sequences used[2] and the availability of clinical-imaging-neuropathological correlations[12,13], have all contributed to an increased importance of MRI in the diagnosis of human prion disease[14], and have been included in the diagnostic criteria for vCJD[8]. Additionally, proton magnetic resonance spectroscopy (MRS)[3], positron emission tomography (PET)[15] and single photon emission computed tomography (SPECT)[16] can provide interesting and novel but sometimes puzzling results in the research of human prion disease.

NEUROIMAGING FINDINGS ON MRI

A symmetric high signal in the caudate and putamen is typical on fluid-attenuated inversion recovery (FLAIR) and diffusion weighted images (DWI) in sCJD[17]. More recent reports have added to the above the significance of “cortical ribbon” hyper-intensity, with a higher sensitivity to DWI[12,18] (Figure (Figure1A1A and andB).B). Nevertheless, the findings in a comprehensive, multicenter international study, strongly argue that characteristic MR lesion profiles may occur in each molecular subtype of sCJD[12]. However, in another study, no abnormality on any MR sequence was found, in 5 of 8 patients with methionine homozygotes (MM2 subtype)[19]. Although the mechanism underlying the MR signal change is controversial[2], a recent small study found that apparent diffusion coefficient (ADC) values, decrease with increasing spongiform change (P < 0.001) and PrP deposition (P = 0.003) in deep gray matter[13] and increased signals in DWI are characterized by reduced ADC values, which quantify regional water diffusion[2] (Figure (Figure1B1B and andC).C). Serial DWI has shown that the extension of high signals increases with disease progression[20,21]. In contrast, initial hyper intensity disappeared in the late disease stages[20,22].

Figure 1
MRI sequences of a patient with sporadic CJD (A-C), inherited CJD (D, E) and variant CJD (F-J). A: Axial T2 weighted image shows a mild signal increase in the left putamen only; B: Axial diffusion weighted images (b = 1000) shows increased signals in ...

In iCJD, incubation periods range from months to up to 30 years and the imaging patterns observed in recipients seem to differ according to the type of donor materials[2]. In human growth hormone recipients, bilaterally symmetric high signals can be observed in caudate head and putamen[2,23]. Similar findings have been reported in case reports of dura mater recipients[24]. However, atrophy is the only imaging finding in larger series of dural grafts[25]. In prion infection due to blood transfusion from asymptomatic donors who later developed vCJD, the pre-mortem MRI is normal[2] or the pulvinar sign becomes evident as the disease clinically progresses[26].

In vCJD, bilateral symmetric high pulvinar signal, as seen on T2 weighted imaging (T2WI), FLAIR (most sensitive) and DWI has been included in the WHO diagnostic criteria[8]. When this pulvinar sign is associated with hyper-intensity in dorsomedial thalamic nuclei, the “hockey stick” sign develops[27] (Figure (Figure1F1F--H).H). The above mentioned pulvinar or hockey stick signs are the most consistent MRI findings in any human prion disease, possibly because only one molecular strain of the disease has been found in vCJD[3]. Finally, in confused or agitated patients with their standard MR sequences degraded by movement artefact, only DWI can provide important diagnostic data[2] (Figure (Figure1I1I and andJJ).

In inherited prion disease, MR changes are non-specific. However, imaging is required to exclude other prion and non-prion diseases. Imaging reports indicate normal findings[5,28], cortical or cerebellar atrophy or decreased basal ganglia signals[28] (Figure (Figure1D1D and andE).E). Also, there is no evidence suggesting the most useful MR sequences in the diagnosis of this inherited disorder[2].

FINDINGS ON PROTON MRS

This non-invasive method is used to assess the spectra of several brain metabolites, such as N-acetylaspartate (NAA), creatine and myo-inositol (MI) and to measure these compounds in both absolute values and ratios, in specific brain regions[2,4]. Considering the NAA a neuronal marker[29], and MI a glial marker[4], proton MRS used as an additional tool along with other MR sequences (FLAIR, DWI, T2WI) is of value in the study of human prion disease. Reduced absolute levels or ratios of NAA and increased MI values, have been reported in sporadic[4,30], variant[30,31], iatrogenic[23] and inherited[32] CJD. The pattern of these metabolic changes on MRS matches the MRI findings on FLAIR, T2[30] and DWI[14]. Nevertheless, important questions still remain to be answered. A recent prospective MRS study[4] showed that the most intense metabolic changes are observed in the thalamus and cerebellum of prion patients (sCJD), while the striatum and cerebral cortex are less affected, despite the existence of positive T2 and DWI findings.

PET AND SPECT FINDINGS

At present, the high cost of PET seems to outweigh the benefit obtained in the investigation of human prion disease. In general, PET reveals generalized hypometabolism that is correlated with histological neuronal loss and astrogliosis[15,33] along with spongiform changes[33]. However, this hypo-metabolism is more pronounced in the cerebellum and cortex than in the thalamus and striatum[15], unmatching the distribution of lesions seen on MRI.

Accordingly, widespread hypoperfusion has been demonstrated using SPECT in all forms of human prion disease[2]. The majority of sCJD patients reveal decreased cerebral perfusion, including the occipital cortex, cerebellum or the entire hemisphere[16]. Also, more regional changes in perfusion with SPECT can be detected in early stages of the disease than MRI changes[34].

CONCLUSION

As different types of disease arise, changes in the neuroimaging patterns of human prion disease continue to puzzle clinicians and researchers alike.

At present, the most consistent MRI change is the pulvinar sign in vCJD patients. When the dorsomedial thalamic nuclei are involved, the “hockey stick” sign provides additional clues[3,8,27]. Since bilateral high signals are observed in the caudate and putamen, and “cortical ribbon” hyper-intensity is found on DWI of sCJD patients[12,17,18], the diagnostic sensitivity of MRI is further augmented. Newer imaging techniques, such as proton MRS and SPECT seem to provide useful data for identifying the patterns in all forms of human prion disease[23,31,32].

Future research should eventually aim at studying the increasing number of “probable” prion cases, through multicenter international studies, utilizing combined imaging modalities, such as serial DWI with MRS, SPECT with MR perfusion imaging and MRI with in vivo PET probe to label prion plaques[2,4,33]. Hopefully, this perspective will elucidate some of the debatable issues presented and the “mist” will start to resolve.

Footnotes

Peer reviewers: Mario Mascalchi, MD, PhD, Professor, Radiodiagnostic Section, Department of Clinical Physiopathology, University of Florence, Viale Morgagni 50134, Florence, Italy; Tarik F Massoud, MB, BCh, BAO, LRCPI, LRCSI, MA, MD, PhD, FRCR, Department of Radiology, University of Cambridge, Addenbrooke’s Hospital, Box 219, Hills Road, Cambridge, CB2 2QQ, United Kingdom

S- Editor Wang JL L- Editor Wang XL E- Editor Zheng XM

References

1. Knight RS, Will RG. Prion diseases. J Neurol Neurosurg Psychiatry. 2004;75 Suppl 1:i36–i42. [PMC free article] [PubMed]
2. Macfarlane RG, Wroe SJ, Collinge J, Yousry TA, Jäger HR. Neuroimaging findings in human prion disease. J Neurol Neurosurg Psychiatry. 2007;78:664–670. [PMC free article] [PubMed]
3. Collinge J. Prion diseases of humans and animals: their causes and molecular basis. Annu Rev Neurosci. 2001;24:519–550. [PubMed]
4. Lodi R, Parchi P, Tonon C, Manners D, Capellari S, Strammiello R, Rinaldi R, Testa C, Malucelli E, Mostacci B, et al. Magnetic resonance diagnostic markers in clinically sporadic prion disease: a combined brain magnetic resonance imaging and spectroscopy study. Brain. 2009;132:2669–2679. [PMC free article] [PubMed]
5. Collinge J. Human prion diseases: etiology and clinical features. In: Growdon JH, Rossor MN, editors. The Dementias. Boston: Butterworth-Heinemann; 1998. pp. 113–150.
6. Zerr I, Pocchiari M, Collins S, Brandel JP, de Pedro Cuesta J, Knight RS, Bernheimer H, Cardone F, Delasnerie-Lauprêtre N, Cuadrado Corrales N, et al. Analysis of EEG and CSF 14-3-3 proteins as aids to the diagnosis of Creutzfeldt-Jakob disease. Neurology. 2000;55:811–815. [PubMed]
7. Steinhoff BJ, Zerr I, Glatting M, Schulz-Schaeffer W, Poser S, Kretzschmar HA. Diagnostic value of periodic complexes in Creutzfeldt-Jakob disease. Ann Neurol. 2004;56:702–708. [PubMed]
8. World Health Organization. The Revision of the Surveillance Case Definition for variant Creutzfeldt-Jakob Disease: Report of a WHO Consultation, Edinburg. World Health Organ Tech Rep Ser. 2004
9. Mastrianni JA. Prion diseases: transmissible spongiform encephalopathies. In: Noseworthy JH, editor. Neurological therapeutics: principles and practice. Oxon: Informa Health Care; 2006. pp. 1163–1168.
10. Burkhard PR, Sanchez JC, Landis T, Hochstrasser DF. CSF detection of the 14-3-3 protein in unselected patients with dementia. Neurology. 2001;56:1528–1533. [PubMed]
11. Krasnianski A, Bartl M, Sanchez Juan PJ, Heinemann U, Meissner B, Varges D, Schulze-Sturm U, Kretzschmar HA, Schulz-Schaeffer WJ, Zerr I. Fatal familial insomnia: Clinical features and early identification. Ann Neurol. 2008;63:658–661. [PubMed]
12. Meissner B, Kallenberg K, Sanchez-Juan P, Collie D, Summers DM, Almonti S, Collins SJ, Smith P, Cras P, Jansen GH, et al. MRI lesion profiles in sporadic Creutzfeldt-Jakob disease. Neurology. 2009;72:1994–2001. [PubMed]
13. Manners DN, Parchi P, Tonon C, Capellari S, Strammiello R, Testa C, Tani G, Malucelli E, Spagnolo C, Cortelli P, et al. Pathologic correlates of diffusion MRI changes in Creutzfeldt-Jakob disease. Neurology. 2009;72:1425–1431. [PubMed]
14. Tschampa HJ, Zerr I, Urbach H. Radiological assessment of Creutzfeldt-Jakob disease. Eur Radiol. 2007;17:1200–1211. [PubMed]
15. Engler H, Lundberg PO, Ekbom K, Nennesmo I, Nilsson A, Bergström M, Tsukada H, Hartvig P, Långström B. Multitracer study with positron emission tomography in Creutzfeldt-Jakob disease. Eur J Nucl Med Mol Imaging. 2003;30:187. [PubMed]
16. Henkel K, Meller J, Zerr I, Schulz-Schaeffer W, Schroeter A, Tschampa HJ, Kretzschmar HA, Becker W, Poser S. Single photon emission computed tomography (SPECT) in 19 patients with Creutzfeldt-Jakob disease. J Neurol. 1999;246 (Suppl 1):490.
17. Schröter A, Zerr I, Henkel K, Tschampa HJ, Finkenstaedt M, Poser S. Magnetic resonance imaging in the clinical diagnosis of Creutzfeldt-Jakob disease. Arch Neurol. 2000;57:1751–1757. [PubMed]
18. Shiga Y, Miyazawa K, Sato S, Fukushima R, Shibuya S, Sato Y, Konno H, Doh-ura K, Mugikura S, Tamura H, et al. Diffusion-weighted MRI abnormalities as an early diagnostic marker for Creutzfeldt-Jakob disease. Neurology. 2004;63:443–449. [PubMed]
19. Krasnianski A, Meissner B, Schulz-Schaeffer W, Kallenberg K, Bartl M, Heinemann U, Varges D, Kretzschmar HA, Zerr I. Clinical features and diagnosis of the MM2 cortical subtype of sporadic Creutzfeldt-Jakob disease. Arch Neurol. 2006;63:876–880. [PubMed]
20. Ukisu R, Kushihashi T, Kitanosono T, Fujisawa H, Takenaka H, Ohgiya Y, Gokan T, Munechika H. Serial diffusion-weighted MRI of Creutzfeldt-Jakob disease. AJR Am J Roentgenol. 2005;184:560–566. [PubMed]
21. Russmann H, Vingerhoets F, Miklossy J, Maeder P, Glatzel M, Aguzzi A, Bogousslavsky J. Sporadic Creutzfeldt-Jakob disease: a comparison of pathological findings and diffusion weighted imaging. J Neurol. 2005;252:338–342. [PubMed]
22. Matoba M, Tonami H, Miyaji H, Yokota H, Yamamoto I. Creutzfeldt-Jakob disease: serial changes on diffusion-weighted MRI. J Comput Assist Tomogr. 2001;25:274–277. [PubMed]
23. Oppenheim C, Zuber M, Galanaud D, Detilleux M, Bolgert F, Mas JL, Chiras J, Meder JF. Spectroscopy and serial diffusion MR findings in hGH-Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry. 2004;75:1066–1069. [PMC free article] [PubMed]
24. Preusser M, Ströbel T, Gelpi E, Eiler M, Broessner G, Schmutzhard E, Budka H. Alzheimer-type neuropathology in a 28 year old patient with iatrogenic Creutzfeldt-Jakob disease after dural grafting. J Neurol Neurosurg Psychiatry. 2006;77:413–416. [PMC free article] [PubMed]
25. Martínez-Lage JF, Poza M, Sola J, Tortosa JG, Brown P, Cervenáková L, Esteban JA, Mendoza A. Accidental transmission of Creutzfeldt-Jakob disease by dural cadaveric grafts. J Neurol Neurosurg Psychiatry. 1994;57:1091–1094. [PMC free article] [PubMed]
26. Wroe SJ, Pal S, Siddique D, Hyare H, Macfarlane R, Joiner S, Linehan JM, Brandner S, Wadsworth JD, Hewitt P, et al. Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: a case report. Lancet. 2006;368:2061–2067. [PubMed]
27. Zeidler M, Sellar RJ, Collie DA, Knight R, Stewart G, Macleod MA, Ironside JW, Cousens S, Colchester AC, Hadley DM, et al. The pulvinar sign on magnetic resonance imaging in variant Creutzfeldt-Jakob disease. Lancet. 2000;355:1412–1418. [PubMed]
28. Zerr I, Giese A, Windl O, Kropp S, Schulz-Schaeffer W, Riedemann C, Skworc K, Bodemer M, Kretzschmar HA, Poser S. Phenotypic variability in fatal familial insomnia (D178N-129M) genotype. Neurology. 1998;51:1398–1405. [PubMed]
29. Kantarci K, Knopman DS, Dickson DW, Parisi JE, Whitwell JL, Weigand SD, Josephs KA, Boeve BF, Petersen RC, Jack CR Jr. Alzheimer disease: postmortem neuropathologic correlates of antemortem 1H MR spectroscopy metabolite measurements. Radiology. 2008;248:210–220. [PMC free article] [PubMed]
30. Pandya HG, Coley SC, Wilkinson ID, Griffiths PD. Magnetic resonance spectroscopic abnormalities in sporadic and variant Creutzfeldt-Jakob disease. Clin Radiol. 2003;58:148–153. [PubMed]
31. Cordery RJ, MacManus D, Godbolt A, Rossor MN, Waldman AD. Short TE quantitative proton magnetic resonance spectroscopy in variant Creutzfeldt-Jakob disease. Eur Radiol. 2006;16:1692–1698. [PubMed]
32. Waldman AD, Cordery RJ, MacManus DG, Godbolt A, Collinge J, Rossor MN. Regional brain metabolite abnormalities in inherited prion disease and asymptomatic gene carriers demonstrated in vivo by quantitative proton magnetic resonance spectroscopy. Neuroradiology. 2006;48:428–433. [PubMed]
33. Goldman S, Laird A, Flament-Durand J, Luxen A, Bidaut LM, Stanus E, Hildebrand J, Przedborski S. Positron emission tomography and histopathology in Creutzfeldt-Jakob disease. Neurology. 1993;43:1828–1830. [PubMed]
34. Arata H, Takashima H, Hirano R, Tomimitsu H, Machigashira K, Izumi K, Kikuno M, Ng AR, Umehara F, Arisato T, et al. Early clinical signs and imaging findings in Gerstmann-Sträussler-Scheinker syndrome (Pro102Leu) Neurology. 2006;66:1672–1678. [PubMed]

Articles from World Journal of Radiology are provided here courtesy of Baishideng Publishing Group Inc